Encyclopedia of Signaling Molecules

Living Edition
| Editors: Sangdun Choi

Eotaxins (CCL11, CCL24, CCL26)

  • Timothy John Williams
  • James Edward Pease
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-6438-9_101627-1


Eotaxin-1: C-C motif chemokine 11; CCL11; Chemokine (C-C motif) ligand 11; Eosinophil chemotactic protein; Eotaxin; SCYA11; Small-inducible cytokine subfamily A (Cys-Cys), member 11 (eotaxin); Small-inducible cytokine A11

Eotaxin-2: C-C motif chemokine 24; CCL24; Chemokine (C-C motif) ligand 24; CK-beta-6; Ckb-6; Eosinophil chemotactic protein 2; MPIF-2; MPIF2; Myeloid progenitor inhibitory factor 2; SCYA24; Small-inducible cytokine subfamily A (Cys-Cys), member 24; Small-inducible cytokine A24

Eotaxin-3: C-C motif chemokine ligand 26; CCL26; IMAC; MIP-4a; MIP-4alpha; SCYA26; TSC-1

Historical Background

Eosinophils are a subpopulation of granulocytes in the blood, identified by their bilobed nucleus and distinctive cytoplasmic granules staining pink with eosin. Eosinophils or related cells are found in mammals and also in other animals including birds, reptiles, amphibians, fish, and insects. Eosinophil-like cells are also present in invertebrates such as the horseshoe crab...


Horseshoe Crab CCR3 Antagonist Motif Chemokine Eosinophil Migration Bone Marrow Eosinophil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.



We thank Asthma UK and the Wellcome Trust for supporting our research.


  1. Abonia JP, Rothenberg ME. Eosinophilic esophagitis: rapidly advancing insights. Annu Rev Med. 2012;63(1):421–34.CrossRefPubMedGoogle Scholar
  2. Ahmadi Z, Hassanshahi G, Khorramdelazad H, Zainodini N, Koochakzadeh L. An overlook to the characteristics and roles played by Eotaxin Network in the pathophysiology of food allergies: allergic asthma and atopic dermatitis. Inflammation. 2016;39(3):1253–67.PubMedGoogle Scholar
  3. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med. 1995;182(4):1169–74.CrossRefPubMedGoogle Scholar
  4. Forssmann U, Uguccioni M, Loetscher P, Dahinden CA, Langen H, Thelen M, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med. 1997;185(12):2171–6.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Gleich GJ. Historical overview and perspective on the role of the eosinophil in health and disease. In: Lee JJ, Rosenberg HF, editors. Eosinophils in health and disease. London: Elsevier; 2013.Google Scholar
  6. He J, Chen Y, Farzan M, Choe H, Gartner S, Busciglio J et al. CCR3 and CCR5 are co-receptors fro HIV-1 infection of microglia Nature 1997;385(6617):645–9.Google Scholar
  7. Huber AK, Giles DA, Segal BM, Irani DN. An emerging role for eotaxins in neurodegenerative disease. Clin Immunol. 2016 (in press).Google Scholar
  8. Humbles AA, Conroy DM, Marleau S, Rankin SM, Palframan RT, Proudfoot AE, et al. Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: analysis in a guinea pig model in vivo. J Exp Med. 1997;186(4):601–12.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med. 1994;179(3):881–7.CrossRefPubMedGoogle Scholar
  10. Main S, Handy R, Wilton J, Smith S, Williams L, Fou LD, et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther. 2006;319(3):1395–404.CrossRefPubMedGoogle Scholar
  11. Mayer MR, Stone MJ. Identification of receptor binding and activation determinants in the N-terminal and N-loop regions of the CC chemokine eotaxin. J Biol Chem. 2001;276(17):13911–6.PubMedGoogle Scholar
  12. Neighbour H, Boulet LP, Lemiere C, Sehmi R, Leigh R, Sousa AR, et al. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2014;44(4):508–16.CrossRefPubMedGoogle Scholar
  13. Palframan RT, Collins PD, Williams TJ, Rankin SM. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood. 1998;91(7):2240–8.PubMedGoogle Scholar
  14. Pease JE, Horuk R. Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4. Expert Opin Drug Discovery. 2014;9(5):467–83.CrossRefGoogle Scholar
  15. Pease JE, Wang J, Ponath PD, Murphy PM. The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation. J Biol Chem. 1998;273(32):19972–6.CrossRefPubMedGoogle Scholar
  16. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest. 1996;97(3):604–12.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Rothenberg ME, Luster AD, Leder P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc Natl Acad Sci USA. 1995;92(19):8960–4.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Sabroe I, Peck MJ, Van Keulen BJ, Jorritsma A, Simmons G, Clapham PR, et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem. 2000;275(34):25985–92.CrossRefPubMedGoogle Scholar
  19. Shinkai A, Yoshisue H, Koike M, Shoji E, Nakagawa S, Saito A, et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol. 1999;163(3):1602–10.PubMedGoogle Scholar
  20. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009;460(7252):225–30.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90–4.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Wise EL, Duchesnes C, da Fonseca PCA, Allen RA, Williams TJ, Pease JE. Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J Biol Chem ASBMB. 2007a;282(38):27935–43.CrossRefGoogle Scholar
  23. Wise EL, Duchesnes C, da Fonseca PCA, Allen RA, Williams TJ, Pease JE. Small antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J Biol Chem ASBMB. 2007b;282(38):27935–43.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2016

Authors and Affiliations

  1. 1.National Heart and Lung InstituteImperial College LondonLondonUK